While cases with concurrent FLT3-ITDhigh (allelic ratio (AR) > 0.5) were previously designated as “intermediate-risk” based on the European LeukemiaNet (ELN) risk stratification [4,5], the newly updated ELN classification now categorizes all cases with NPM1-mutated AML with FLT3-ITD co-mutation as intermediate-risk group regardless of AR [6]. The gene discussed is NPM1; the disease is acute myeloid leukemia.